01 — Mission
Research first, always.
Cytosomatic Labs is a preclinical neuroscience organisation focused on disciplined, reproducible science.
About
An early-stage neuroscience lab, saying so plainly
Cytosomatic Labs was founded to pursue one question: can neurological function be repaired rather than merely managed? We are pursuing it in the laboratory, in public, and in collaboration — and we are careful about the difference between what we hope and what we have shown.
Who we are
- 01Mission
- 02Governance
- 03Principles
02 — Governance
Accountable by design.
Clear oversight, documented methods and independent review guide every study we run.
03 — Principles
Evidence over hype.
We publish what we learn and state plainly what we do not yet know.
Mission
Precision neuroscience for the patients most often excluded
Neurodegenerative and complex neurological patients are often underserved by therapies designed for the average case. Our work targets that gap directly: characterise the neural dysfunction, engineer a correction, and measure restored function honestly.
We are deliberately a research organization first. Our near-term output is evidence — validated assays, published methods, reproducible datasets — because that is what any future neuroscience programme must be built on.
Accuracy before ambition
We describe our stage precisely. Preclinical work is called preclinical, and nothing is framed as a treatment until the evidence supports it.
Data belongs to the collaboration
Partners receive raw data and method files, not curated summaries. Reproducibility is only real if someone else can check the work.
Patients define the endpoint
Restored function, fewer flares, more good days — those are the outcomes that justify the science.
Small team, deep focus
Three programmes, one platform. We would rather do a narrow thing properly than a broad thing loosely.
Institutional governance
How decisions are made and checked
Governance is documented rather than implied. Each function below has a named owner, a defined scope and a record that a collaborator can request.
Founder & research direction
Programme selection and capital allocation
Programmes are selected against a written mechanism hypothesis and a named failure condition. Funding is released per phase gate, not per calendar year.
Scientific advisory review
Independent methodological critique
Practising neurologists, neuroimmunologists and neuroradiologists review study design and endpoints before bench time is committed.
Quality function
SOPs, records and reproducibility
Every assay carries an SOP, a version history and inter-operator reproducibility records. Negative and null results are retained in the same record as positive ones.
Research ethics & scope
Boundaries of the work
Cytosomatic Labs is preclinical. It does not treat patients, run clinical trials, sell products or provide medical advice, and it does not describe findings as clinical outcomes.
Data governance
Collaborator data access
Partners receive raw data and method files alongside any summary. Human-derived material is handled under documented consent and retention terms.
Disclosure
Stage and funding transparency
The venture is privately funded and states its stage plainly on every public page. Roadmap phases are only marked complete when their records support it.
Roadmap
Where we are, honestly
Phase I — Foundation
CompleteResearch platform assembled: instrumentation, data schema, SOP library and quality records.
Phase II — Characterisation
In progressNeural and neuroimmune profiling across neurodegenerative cohorts; candidate biomarker validation.
Phase III — Construct validation
NextNeural cell-therapy construct comparison in primary human cells and co-cultures, with safety and mechanism readouts.
Phase IV — Translational readiness
PlannedIND-enabling study design with clinical advisors, subject to Phase III outcomes.